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Abstract: p28 is a 28-amino acid peptide fragment of the cupredoxin azurin derived from 
Pseudomonas aeruginosa that preferentially penetrates cancerous cells and arrests their 
 proliferation in vitro and in vivo. Its antitumor activity reportedly arises from post-translational 
stabilization of the tumor suppressor p53 normally downregulated by the binding of several 
ubiquitin ligases. This would require p28 to specifically bind to p53 to inhibit specific ligases 
from initiating proteosome-mediated degradation. In this study, atomic force spectroscopy, 
a nanotechnological approach, was used to investigate the interaction of p28 with full-length 
p53 and its isolated domains at the single molecule level. Analysis of the unbinding forces and 
the dissociation rate constant suggest that p28 forms a stable complex with the DNA-binding 
domain of p53, inhibiting the binding of ubiquitin ligases other than Mdm2 to reduce  proteasomal 
degradation of p53.
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Introduction
The p53 protein is a transcription factor that acts as a tumor suppressor by playing an 
essential role in preventing inappropriate cell proliferation and in maintaining genome 
integrity. It is stabilized by post-translational modifications in response to different 
stress signals, increasing its intracellular levels and activating the transcription of 
downstream target genes that regulate cell-cycle arrest, DNA repair, and apoptosis.1,2 
p53 is a 393-residue protein with three functional domains: an N-terminal domain 
(NTD, aa 1–93), a core DNA-binding domain (DBD, aa 102–292), and a C-terminal 
domain (CTD, aa 293–393) that are responsible for its transcriptional activation, DNA-
binding, and tetramerization functions, respectively.3,4 The activity of p53 is tightly 
regulated through post-translational modification, localization, and degradation.5 Its 
major negative regulator is the Mdm2 oncoprotein that inhibits its transcriptional 
activity,6 favors its nuclear export,7 and acts as an E3 ubiquitin ligase, targeting p53 
for proteasomal degradation.8 The regulatory function of Mdm2 is exerted through 
formation of a complex with p53.6,9
The central role of p53 in safeguarding the genome integrity provides an attractive 
target for anticancer drugs that can stabilize it, interfere with its downregulatory 
pathway,10,11 and enhance its tumor-suppressor function in cancer cells. One such agent, 
azurin, a copper-containing, electron-transfer protein secreted by the opportunistic 
pathogen Pseudomonas aeruginosa, has significant anticancer activity in vitro12–15 
and in vivo.12,14 The antiproliferative activity of azurin is based on the stabilization 
and subsequent increase in intracellular concentration of p53.12–15 A single-molecule 
International Journal of Nanomedicine 2011:6submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3012
Bizzarri et al
atomic force spectroscopy (AFS) experiment has shown 
that a stable complex is formed between full-length p53 
and azurin.16 However, biological as well as computational 
studies have reported that azurin binds to either the NTD 
of p5314,17,18 or its DBD.14,19,20 Site-direct mutagenesis12,13,15 
and computational investigations20 have revealed that the 
two methionines, located at positions 44 and 64 within a 
hydrophobic patch of azurin are crucial for the interaction 
with p53.
Although azurin preferentially enters cancer relative to 
normal cells,21 a 128-amino acid protein could display some 
immunogenicity, a potentially significant side effect, that 
compromises its pharmaceutical efficacy.12 Since peptide 
fragments of azurin could provide therapeutic molecules 
with the same cytotoxicity, delivery, and target specificity 
of the whole protein, but with potentially fewer side effects, 
truncated versions of azurin have been investigated for 
 anticancer activity. Amino acids 50–77 of azurin form a 
2.9 kDa peptide fragment that encompasses the azurin α-helix 
and retains the preferential penetration of the whole protein, 
but also its antitumor activity in vitro and in vivo.21–24 The 
antiproliferative activity appears to result from aa residues 
11–18 of p28 (61–69 of azurin) binding to p53 in a region 
that does not inhibit the binding of Mdm2 or subsequent 
ubiquitination.23 Since the molecular details and the kinetics 
of its interaction with p53 and, more importantly, with what 
domain(s) have not yet been clarified, a detailed study of the 
p28–p53 interaction could provide significant information on 
p28 action at the molecular level.
In the present work, the kinetic properties of the 
interaction of p28 with the full-length p53 and its DBD and 
NTD at a single-molecule level were investigated by AFS, 
while the interaction with the CTD has been excluded on 
the basis of competition assays results.23 AFS is an innovative 
 nanotechnology, suitable for measuring intermolecular 
forces down to the piconewton range, at single-molecule 
resolution, in near-physiological conditions without any 
labeling and using an extremely low amount of substances. 
As such, it provided detailed information on the interaction 
strength and kinetics of these biomolecular partners, 
complementing  traditional biochemical and molecular 
approaches.25 The kinetic parameters determined from force 
spectroscopy experiments suggest a bio-recognition process 
occurs between p28 and the DBD of p53, while almost no 
interaction is registered with the NTD. This strongly suggests 
that p28 undergoes a specific interaction only with the DBD 
of p53 and provides a first look at the kinetics of the reaction 
that underlies the anticancer activity of p28.
Methods
Protein expression and purification
The human p53 gene encoding aa 1–93 was amplified by 
polymerase chain reaction (PCR) with pUC18p53, kindly 
provided by Professor Nobuo Tsuchida, Department of 
Molecular Cellular Oncology and Microbiology, Tokyo, 
Medical and Dental University. Primer set used was 5′-AAA 
GGG GGA TCC ATG GAG GAG CCG CAT CAG ATC 
CT-3′ and 5′-AAA AGG GAA TTC TCA CAG GGG CCA 
GGA GGA GGG-3′ (Genenco, Firenze, Italy). 10 pmol 
of each primer was added to 20 ng of template DNA and 
12.5 mL of 23 PCR HotStartTaq™ mix (Qiagen, Hilden, 
Germany) in a final volume of 25 mL. The amplified  fragment 
was digested by Bam HI and Eco RI (Invitrogen, Carlsbad, 
CA) and ligated into pGEX-2T vector in frame with the 
glutathione S-transferase (GST) gene sequence. The fusion 
protein, expressed in Escherichia coli BL21 cells transformed 
with the pGEX-2T (1–93) plasmid, was purified as previ-
ously described.26
Also, purification of full-length p53 (aa 1–393) and 
its DBD (aa 94–288) followed a standard GST method. 
Briefly, E. coli BL21 DE3 having pGEX-4T-wtp53 or 
pGEX- 4T-DBD-p53 plasmid DNA were grown at 37°C 
to optical density measured at a wavelength of 600 nm 
of 0.4.  Bacteria were incubated for an additional 3 hours 
with 0.5 mM isopropyl-1-thio-β-galactopyranoside under 
vigorous shaking. Cells were lysed in phosphate-buffered 
saline (PBS) containing 0.1% Triton® X-100, 1 mM dithio-
threitol (DTT), and protease inhibitors. After centrifugation, 
supernatant fractions were incubated with glutathione-
Sepharose™ beads (G4510; Sigma, St Louis, MO). GST-
fusion proteins were eluted with 50 mM Tris-HCl pH 8.0 
containing 10 mM glutathione (G4251; Sigma) and 1 mM 
DTT, and incubated with either thrombin or Factor Xa 
protease (Amersham Biosciences, Piscataway, NJ). After 
incubation at room temperature for 16 hours, thrombin or 
Factor Xa protease was removed by P-aminobenzamidine-
agarose or anti-factor Xa-agarose beads (Sigma). GST-free 
p53 and its derivatives were dialyzed against storage buffer 
(50 mM Tris-HCl pH 7.5, 1 mM MgCl
2
, 0.5 mM DTT). The 
quality, correct folding, and purity of recombinant proteins 
were subsequently verified.27
Tip functionalization
The 28-amino acid (Leu50-Asp77, 2.9 kDa) fragment of 
azurin was anchored to the AFS silicon nitride cantilever 
(Veeco Instruments, Santa Barbara, CA) by means of a 
cysteine residue conjugated to the NH
2
-terminus to create 
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Figure 1 Immobilization strategies of peptide and proteins to the tip or substrate. (A) p28 is bound to the amino-silanized tip via a Peg crosslinker. (B) p53, or alternatively 
its DBD or NTD, is immobilized on glass slides via a chemical platform involving sequentially linked amino-silane and glutaraldehyde, thus targeting aminic groups of lysine 
residues exposed on the protein surfaces (see Materials and methods section for details).
Abbreviations: APTes, 3-aminopropyl-triethoxysilane; DBD, DNA-binding domain; MAL, maleimide; NTD, N-terminal domain; Peg, polyethylene glycol.
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p29 (Cys-p28, 3.0 kDa). The tips were cleaned in acetone 
for 10 minutes, dried with a stream of nitrogen, and 
ultraviolet (UV)  irradiated for 30 minutes to expose hydroxyl 
groups. Tips were then immersed in a solution of 2% (v/v) 
3-aminopropyl-triethoxysilane (APTES) (Acros Organics, 
Geel, Belgium) in chloroform, incubated for 2 hours at 
room temperature, rinsed in three changes of chloroform, 
and dried with nitrogen. Silanized tips were immersed 
in 1 mM N-hydroxysuccinimide-polyethylene glycol-
maleimide (NHS-PEG-MAL), molecular weight 1395 Da, 
9.5 nm in length (Thermo Scientific Inc, Waltham, MA) 
and dissolved in dimethylsulfoxide (DMSO) for 3 hours at 
room temperature. The PEG spacer contains an NHS-ester 
group at one end, which reacts with amino-silane molecule 
to form an amide bond and a maleimide group at the other 
end, which reacts with the sulfhydryl group of cysteine 
residue linked to the NH
2
-terminus of p28. Tips were then 
washed in three changes of DMSO to remove the unbound 
linker, rinsed with Milli-Q® (Millipore, Bellerica, MA) water, 
dried with nitrogen, then incubated with 50 µL of a 10 µM 
solution of p28 in 50 mM PBS pH 7.5 overnight at 4°C. 
The tips were then gently rinsed and stored in buffer at 4°C. 
A schematic representation of tip functionalization is shown 
in Figure 1A.
Preparation of the protein substrates
The full-length p53, its DBD, and its NTD, were  individually 
immobilized on glass slides previously cleaned for 5  minutes 
in acetone, dried under a stream of nitrogen and then 
UV  irradiated for 30 minutes. After immersion in 0.3 M 
APTES in chloroform and incubation for 3 minutes at room 
 temperature, they were rinsed in three changes of chloroform 
and dried with nitrogen. The glass slides were subsequently 
incubated with a solution of 1% glutaraldehyde (Sigma-
Aldrich, St Louis, MI) in Milli-Q water for 10 minutes at 
room temperature, rinsed carefully with Milli-Q water, and 
dried with nitrogen. Fifty µL of a 0.8 µM p53, p53 DBD 
or p53 NTD in 50 mM PBS pH 7.5 were poured onto this 
amine-reactive surface, incubated overnight at 4°C, gently 
washed with PBS, and stored in buffer at 4°C. A schematic 
representation of the substrate functionalization is shown 
in Figure 1B.
Atomic force microscopy (AFM) imaging 
and force spectroscopy
A Nanoscope IIIa/Multimode atomic force microscope 
(Digital Instruments, Santa Barbara, CA) was used to  perform 
force spectroscopy. Imaging of full-length p53, p53 DBD, 
and p53 NTD substrates were imaged by tapping mode 
AFM, with an amplitude set point corresponding to the 95% 
of the free amplitude value. The cantilever nominal spring 
 constant, k
nom
, was 0.5 N/m. The substrate was scratched 
to get a qualitative indication about the protein monolayer 
height as described by Funari et al.27
Force measurements were carried out in PBS  buffer 
(50 mM K
3
PO
4
, 150 mM NaCl, pH 7.5) using force 
 calibration mode AFM. The cantilevers used to perform 
force spectroscopy studies had a nominal spring constant, 
k
nom
, of 0.01 N/m. The effective spring constant, k
eff
, 
was  determined by the procedure reported by Hutter and 
 Bechhoefer.28 A relative trigger of 50 nm was applied to limit 
the maximum contact force applied by the tip on the protein 
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Figure 2 schematic representation of a force–distance cycle carried out in the 
atomic force spectroscopy experiment. A ligand-functionalized tip is approached to 
a surface covered by immobilized receptor (point 1); the cantilever begins to deflect 
upward due to the ligand–receptor intermolecular repulsive forces (point 2); the 
two partners can interact, and when the cantilever applies the maximum contact 
force upon the substrate, the approaching phase is stopped (point 3); the cantilever 
begins to retract, reaches the baseline deflection and begins to bend downward 
due to the attractive interaction force displayed by the ligand–receptor complex 
(point 4); when the force exerted by the cantilever overcomes the stability of the 
complex bonds, the cantilever jumps off, returning to its initial position (point 5). 
see Funari et al27 for a detailed description.
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monolayer to 0.5 nN. A ramp size of 150 nm was set, and an 
encounter time of 100 ms established. The approach velocity 
was set at a value of 50 nm/s, with the retraction velocity 
increased from 50 to 4190 nm/s. Loading rate, defined as 
r = dF/dt, was determined according to the relationship 
r = dF/dt = kv, where k is the cantilever spring constant. 
Correspondingly, the nominal loading rate, obtained by using 
the nominal spring constant, k
nom
, was found in the range 
0.5–42 nN/s. The effective  loading rate was determined by 
replacing the nominal cantilever constant with the effective 
one, k
sys
, to take into account that molecules (ie, proteins 
and/or  linkers) tied to an AFM tip make the cantilever spring 
constant change. The k
syst
 values were obtained from the slope 
of each retraction curve immediately prior to the unbinding 
event.29–31 All blocking experiments were conducted at the 
nominal loading rate of 7 nN/s.
Results
Interaction of p28 with full-length p53
All experiments were performed using AFS, a single-
 molecule technique that complements traditional proteomic 
and molecular biology approaches for the functional analysis 
of biorecognition events.25,32 In a typical AFS experiment, 
a ligand is anchored to the AFS tip while the receptor is 
immobilized onto a substrate. Force–distance curves are 
thus performed cyclically on the tethered system, as sketched 
in Figure 2 and described in the legend. Briefly, the tip is 
approached to the substrate until the ligand and the receptor 
are brought into close proximity and can interact to form a 
complex. The cantilever then retracts from the surface, and 
when the force that it exerts overcomes the stability of the 
complex bonds, a sudden jump in the deflection occurs as a 
consequence of the complex dissociation.
Hence, one key requisite to investigate ligand–receptor 
interaction by AFS is a robust attachment of ligand and 
receptor on their respective AFM supports, preferably 
through covalent bonds, which are generally stronger than 
those characterizing protein–protein interaction.25,33 Strong 
immobilization of the two partners ensures the stability of 
the tethered system over time allowing repeated approach/
retraction cycles. In this respect, the NH
2
-terminal of 
p28 is conjugated to a cysteine residue whose SH group 
reacts with the MAL group of a flexible 9.5 nm-long PEG 
polymer covalently linking the p28 peptide to the AFS tip 
(Figure 1A). The linker increases the flexibility and the 
re-orientation freedom of the peptide when the AFM tip 
approaches the protein monolayer. This favors the bio-
recognition process.34 Moreover, during the tip-retraction, 
the linker undergoes a stretching process whose unique 
features assist in discriminating specific and nonspecific 
unbinding events.25,33
Full-length p53 molecules are immobilized on a glass 
slide by targeting the amine groups of the lysine residues 
exposed on the protein surface (Figure 1B). The presence of 
several lysine residues available for the reaction is susceptible 
to generate statistically random orientations of the proteins 
on the substrate. This immobilization strategy could generate 
some configurations that might result unfavorably for the 
bio-recognition event (see below).
Before proceeding with AFS measurements, the 
 morphology of p53 proteins immobilized on the glass 
slides were analyzed by imaging AFM using a bare tip. The 
 presence of a homogenous layer of p53 with discernible 
single  proteins was observed. To verify the presence of a 
monolayer and define its height, a bare tip was thus used to 
scratch the substrate, working in contact mode as described 
in Funari et al27 (results not shown).
With a functionalized tip thousands of force curves were 
thus recorded on such a substrate with an intermediate degree 
of coverage (condition also suggested by Gilbert et al),35 at 
several distinct points in which a corresponding percentage 
of specific events were observed. The approach speed was 
kept constant while the retraction one, v, was varied from 
50 to 4190 nm/s.
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Figure 3 (A) histograms of the unbinding forces for the p28/p53 complex before 
and after blocking. The most probable unbinding force value was determined from 
the maximum of the main peak of the histogram before blocking. All measurements 
were performed at a loading rate of 7 nN/s. (B) histogram of the unbinding lengths 
for the p28/p53 complex, evaluated for the same collection of force curves as in (A). 
The continuous line is the fit by a Gaussian centered at 12 nm and with a standard 
deviation of 5.6 nm.
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As collected force curves can significantly differ in AFS 
unbinding experiments in the single molecule regime,25,32 
force curves were accepted whose retraction portion, before 
the jump-off, exhibited a nonlinear trend starting and  ending 
at the zero-deflection line where the nonlinear trend is 
 attributed to the viscoelastic properties of the PEG linker 
under stretching.36,37 When multiple jumps were observed, 
which could be due to subsequent rupture of the complex 
bonds, the curves were accepted if the last jump started 
and ended at zero deflection, with the last jump taken as 
 representative of the unbinding process.
The unbinding frequency, defined as the ratio between 
the number of accepted unbinding events and total number 
of the collected force curves, was found to be about 20% at 
a loading rate of 7 nN/s. This frequency could potentially be 
affected by the presence of unfavorable binding  geometries 
and by steric hindrance.16,27,38 However, studying the 
 frequency of unbinding as a function of the surface  coverage, 
no signif icant change was found. The relatively low 
unbinding frequency, detected even when specific interaction 
occurs, was thus to be ascribed to the random orientation 
resulting from the  immobilization strategy. Interestingly, the 
unbinding frequency, observed to be consistent with values 
previously reported for other biological interactions,27,39,40 
was dependent on the loading rate, initially increasing, 
reaching a maximum, and decreasing as previously 
described.27
As the unbinding force for each curve is the product of 
cantilever deflection (d, Figure 2) and its effective spring 
constant (k
eff
), force histograms correspond to the different 
loading rates at which force spectroscopy measurements were 
conducted. Working on the chosen intermediate substrate 
coverages, the histograms of the unbinding forces, ie, at 
a loading rate of 7 nN/s (Figure 3A), exhibit essentially a 
single mode distribution, slightly skewed toward high force 
values. The asymmetric shape, similar to that observed in 
other systems, could be due to some factors such as the het-
erogeneity in chemical bonds or spacer length, or a residual 
occurrence of a few multiple binding events.39,41,42 On this 
basis, in this present study, the most probable unbinding force 
was determined from the maximum of the main peak of each 
histogram. At a loading rate of 7 nN/s, an unbinding force 
value of 82 pN was found (Figure 3A), which falls within 
the range reported for other specific biological interactions 
at similar loading rates.43 Also found was that the unbinding 
force values and the widths of their corresponding distribu-
tions increased with an increase in loading rate, as reported 
previously.16,27,44
Blocking experiments on the p28/p53 complex 
 demonstrated that the observed unbinding events arise from 
a specific recognition process. Indeed, after incubation of 
the p53-functionalized substrate with 30 µM free p28, the 
unbinding frequency was reduced about 55%,  indicating 
 formation of a p28/p53 complex was specif ic. Upon 
increasing the concentration of the blocking agent, a higher 
attenuation was not registered. The persistence of residual 
unbinding activity after blocking has also been reported for 
other force spectroscopy experiments and could be related 
to the forced interaction between the two partners, induced 
by the experimental design.45 Importantly, the similarity in 
force histograms before and after blocking (see Figure 3A) 
indicates the corresponding interactions may be similar. 
The specificity of the p28/p53 interaction was further 
verified by distribution analysis of the linker extension 
from zero distance to the position of the complex rupture 
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Figure 4 Plot of the unbinding forces versus the logarithm of the loading rates for 
the p28/p53 interaction. statistical errors are given by standard deviation. The line is 
obtained by fitting the experimental data by the Bell-Evans model (Equation 2).
Abbreviations: koff, dissociation rate constant; F*, the most probable unbinding 
force; xβ, width of the potential barrier along the direction of the applied force.
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in a force-distance curve. The unbinding length distribution 
exhibited a single-mode distribution centered at 12.0 nm 
with a standard deviation of 5.6 nm (Figure 3B), which is 
in good agreement with the extension expected from the 
stretching of the 9.5 nm long PEG during the unbinding 
process.45 The unbinding process which the p28/p53 complex 
undergoes under the influence of an external loading force 
can be treated within the theoretical context of the Bell-
Evans model.46,47 According to this model, the application 
of an external force (F) modifies the energy profile of the 
unbinding process, lowering the activation energy barrier, 
resulting in an exponential increase of the dissociation rate 
constant k
off
(F) with the applied force
 k
off
(F) = k
off
 ⋅ exp[F xβ/kBT] (1)
where k
off
(F) and k
off
 are the dissociation rate constant in 
the presence of and without any applied force, respectively, 
xβ is the width of the potential barrier along the direction of 
the applied force, k
B
 is Boltzmann’s constant, and T is the 
absolute temperature.
Assuming that the applied force F increases linearly with 
a constant loading rate r, the most probable unbinding force, 
F*, at a fixed value of loading rate is given by:
 F* = k
B
T/xβ ⋅ ln[r xβ/(koff ⋅ kBT)] (2)
This expression predicts a linear relationship between the 
most probable unbinding force, F*, and the natural logarithm 
of the effective loading rate r. F* has been determined from 
the maximum of the main peak of each unbinding force his-
togram, and r is given by the product between the retraction 
velocity and the spring constant of the entire system, k
syst
, 
determined from the slope of the force versus distance for 
each retraction curve, as described in the Methods section.
Therefore, by plotting F* versus the natural logarithm of 
the effective loading rate r, the kinetic parameters k
off
 and 
xβ can be obtained from the slope and intercept of a linear 
fit. Figure 4 shows the dynamic force spectrum obtained 
by fitting the plot of F* versus log (r) with Equation 2. The 
spectrum shows, in the range of loading rates under consid-
eration, a single regime indicative of a single energy barrier 
and unique transition state of the reaction and provided 
values of 0.47 ± 0.02 nm for xβ and 0.13 ± 0.03 s−1 for koff. 
The association rate constant (k
on
) for the p53/p28 complex 
has been estimated from the expression k
on
 = N
A
V
eff
/t
0.5
, 
where N
A
 is the Avogadro’s number, V
eff
 is the effective 
volume of a half-sphere with radius r
eff
 around the tip, and 
t
0.5
 is the time for the half-maximal binding probability, 
given by t
0.5
 = 2 r
eff
/v, where v is the approach speed of the 
cantilever.16,45 To  estimate t
0.5
, the interaction time between 
the proteins was varied during the force distance cycles, 
and an exponential increase was observed in the unbinding 
frequency with contact time, until a plateau was reached. 
A t
0.5
 of 0.05 seconds was found, and then, by assuming 
a r
eff
 of 4 nm, a k
on
 = 1.8 × 104 M−1 s−1 was obtained. The 
 dissociation constant (K
D
 = k
off
/k
on
) for the complex between 
p53 and p28 was about 7 × 10−6 M. Interestingly, K
D
 is 
located in an “affinity region” between the transient azurin/
cytochrome c551 complex (K
D
 in the range of 10−4–10−6 M) 
and that reported for antigen/antibody pairs (K
D
 in the order 
of 10−7–10−11 M).38
Interaction of p28 with the p53 DBD  
and NTD
The single-molecule interaction of the p28 peptide fragment 
of azurin with the DBD and NTD of p53 was studied. The 
experiments (substrate coverage, immobilization strategies, 
and sampling procedures) were conceived in order that the 
AFS results could be comparable for the different proteins 
immobilized on the substrate on a statistical basis. As already 
mentioned, the interaction with the p53 CTD has not been 
investigated, since competition assays with p53 site-specific 
antibodies demonstrate that p28 has no contact with p53 
CTD aa residues.23
Concerning the p28/DBD interaction, at a loading 
rate of 7 nN/s, an unbinding frequency of about 25% was 
obtained. The most probable unbinding force, extracted 
from the maximum of the main peak of the unbinding 
forces histogram (Figure 5A), was 95 pN. The unbinding 
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Figure 5 (A) histograms of the unbinding forces for the p28/DBD complex before 
and after blocking. The most probable unbinding force value was determined from 
the maximum of the main peak of the histogram before blocking. All measurements 
were performed at a loading rate of 7 nN/s. (B) histogram of the unbinding lengths 
for the p28/DBD interaction, evaluated for same collection of force curves as in (A). 
The continuous line is the fit by a Gaussian centered at 12.1 nm and with a standard 
deviation of 3.7 nm.
Abbreviation: DBD, DNA-binding domain.
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Figure 6 Plot of the unbinding forces versus the logarithm of the loading rates for 
the p28/DBD complex. statistical errors are given by standard deviation. The line is 
obtained by fitting the experimental data by the Bell-Evans model (Equation 2).
Abbreviations: DBD, DNA-binding domain; koff, dissociation rate constant; F*, the 
most probable unbinding force; xβ, width of the potential barrier along the direction 
of the applied force.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3017
p28 interaction with p53 and its domains with AFs
frequency and unbinding force values are slightly higher than 
those corresponding to the p28/p53 interaction.  Blocking 
by incubation of the DBD-functionalized substrate with 
30 µM free p28 produced a 60% reduction in the unbinding 
frequency  (Figure 5A), indicative of the specificity of the 
p28/DBD complex. The force histograms, before and after 
blocking, also show a similar distribution. The specificity of 
the p28/DBD interaction is also observed in the unbinding 
lengths, which show a single-mode distribution centered at 
12.1 nm and with a standard deviation of 3.7 nm  (Figure 5B). 
 Measurement of highly probable unbinding forces over 
the range of five loading rates investigated (from 0.5 to 
42.0 nN/s) and application of Equation 2 led to the linear 
plot shown in Figure 6 from which an xβ of 0.46 ± 0.05 nm 
and a k
off
 of 0.012 ± 0.006 s−1 were extracted. While the xβ 
value is essentially comparable to that calculated for the 
p28/p53 complex, the k
off
 value is, remarkably, one order 
of magnitude lower and displays a much higher spread. 
On the other hand, the association rate constant, k
on
, for the 
p28/DBD complex, measured as previously described, is 
1.9 × 104 M−1 s−1, close to that of the p28/p53 interaction. 
The k
on
 and k
off
 values yielded for the p28/DBD complex a 
K
D
 of 6.3 × 10−7 M.
The same experimental approach used to study the p28/
p53 and p28/DBD interaction, was used to investigate the 
possible interaction of p28 with the NTD of p53. p28 was 
anchored to the AFS silicon nitride tip, while the NTD was 
immobilized on a glass slide (Figure 1). The  corresponding 
force curves were recorded maintaining a constant  forward 
velocity and varying the retraction speed from 50 to 
4190 nm/s. At a loading rate of 7 nN/s, there was minimal 
number of unbinding events which yielded a negligible 
unbinding frequency. Since the observed events were not 
statistically significant, it is reasonable to assert that there is 
no specific interaction between p28 and the NTD.
Discussion
The specific interaction of the azurin-derived peptide, p28, 
with full-length p53, its DBD, and its NTD was investigated 
for the first time at a single-molecule level by means of AFS. 
The technique enabled the strength and kinetics of complexes 
to be probed under the application of an external force, under 
nearly native conditions, and without any labeling. The AFS 
approach revealed that a specific interaction occurs between 
p28 and p53, leading to the formation of a stable complex. 
Interestingly, the unbinding force, dissociation constant, and 
kinetic parameters of the complex are comparable to those 
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measured by AFS for the p53 interaction with azurin, to 
which p28 belongs.16
The interaction of p28 with full-length p53 appears 
confined to the DBD core domain through formation 
of a stable complex. Interestingly, it was found that the 
 lifetime τ (τ = 1/k
off
) of the DBD/p28 complex is ten times 
longer than that of the p28–p53 association, probably as 
a  consequence of the DBD tendency to form aggregates48 
that could wrap p28 and exert a steric hindrance to its exit 
from the complex. The possible DBD aggregation, however, 
seems not to affect the association phase of the interaction 
as the similar k
on
 calculated for the DBD-p28 and p53-p28 
complexes suggest.
The finding of a specific and stable p28–DBD interaction 
points out more precisely which region of full-length p53 is 
involved in the interaction with p28, with respect to what has 
been previously reported in in-vitro studies.23 In addition, the 
results are in line with those of a computational docking study 
predicting that p28 and the DBD of p53 undergo a  molecular 
association characterized by low, negative  binding free 
energy,49 high shape complementarity, and several hydrogen 
bonds at the interface. Indeed, in that study the best predicted 
complex between DBD and p28 has been shown to involve 
the DBD aa residues 96–103, just close to its S1 strand and, 
at least in part, its L2 loop (aa 164–170).
The occurrence of a stable complex between the DBD 
and p28 suggests that the p28 anticancer activity may be 
related to its ability to inhibit the binding of E3 ligases, 
other than Mdm2, ie COP1, Pirh2, and perhaps TOPORS 
and ARF-BP150–52 to the DBD, and reduce the proteasomal 
degradation of p53. In this respect, competitive assays of 
the DBD–p28 interaction by using these ligases, would 
provide significant insight into the p28 mechanism of 
action.
The DBD is not only involved in the control of the p53 
downregulation, but it is above all, the domain necessary for 
the binding of the tumor suppressor to DNA. Since mutations 
within the DBD are often connected with p53 loss of function 
and subsequent tumor proliferation, it could be interesting 
to investigate the possibility that p28 could interact with 
mutated forms of DBD and enhance apoptosis. Here, p28 
could potentially produce a conformational reversion of 
mutant p53, reactivating its wild-type function.
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